Key facts
- This page summarizes Pascal Bamford's Form 4 filing for Akoya Biosciences, Inc. (AKYA).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 04 Mar 2025, 17:09.
Pascal Bamford - 01 Mar 2025 Form 4 Insider Report for Akoya Biosciences, Inc. (AKYA)
- Reporting relationship
- Chief Clinical Officer
- Issuer ticker
- AKYA
- Reported as of
- 01 Mar 2025
- Net transaction value
- -$6,276
- SEC form
- 4
- Accepted by SEC
- 04 Mar 2025, 17:09:48 UTC
- Prior SEC filing
- 21 Nov 2024
- Next SEC filing
- 02 Jun 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Pascal Bamford by Brian McKelligon, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Pascal Bamford filed Form 4 for Akoya Biosciences, Inc. (AKYA) on 04 Mar 2025.
Change
- Previous filing in this sequence was filed on 21 Nov 2024.
- Current net transaction value: -$6,276.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AKYA
transaction
Common Stock
Tax liability
- Transaction value
- $2,091
- Shares
- -1,283
- Change %
- -0.61%
- Price
- $1.63
- Shares after
- 208,975
- Date
- 01 Mar 2025
- Ownership
- Direct
- Footnotes
- F1
AKYA
transaction
Common Stock
Tax liability
- Transaction value
- $4,184
- Shares
- -2,567
- Change %
- -1.2%
- Price
- $1.63
- Shares after
- 206,408
- Date
- 01 Mar 2025
- Ownership
- Direct
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents shares withheld to cover taxes on a restricted stock unit award previously granted on February 23, 2023, which vests in four (4) annual equal installments beginning on March 1, 2024 and annually thereafter until fully vested.
Footnote F2
Represents shares withheld to cover taxes on a restricted stock unit award previously granted on February 22, 2024, which vests in four (4) annual equal installments beginning on March 1, 2025 and annually thereafter until fully vested.